TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05531097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31679
Description: Single or multiple oral doses of HSK31679

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT06091384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training
Description: Using a handheld device, participants will perform 30 breaths per day at 75% of maximal inspiratory pressure, six days a week, during 6 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle strength training
Description: Using a handheld device, participants will perform 30 breaths per day at 75% of maximal inspiratory pressure, six days a week, during 6 weeks.
Study: NCT05678114

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: Myo-inositol (4g/die)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: Myo-inositol (4g/die)
Study: NCT06450561

Intervention type: OTHER
Intervention: cardiovascular event
Description: In this single group observational trial the exposure of interest is a cardiovascular event.
Study: NCT04935515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins
Description: Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins
Description: Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral low dose steroid
Description: Low dose oral methyl prednisolone was added.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Antibiotics with Low dose steroid.
Description: Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral anti-coagulant
Description: Rivaroxaban was given for minimum 4 weeks depending on D dimer levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral anti-coagulant
Description: Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
Study: NCT05832983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Meditation
Description: In private exam room, the study registered nurse (RN) will read a prepared two minute guided meditation to patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Meditation
Description: In private exam room, the study registered nurse (RN) will read a prepared two minute guided meditation to patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: In private exam room, study RN will first affix an Elequil Aromatab to patient's clothing on either their upper arm or chest (whichever the patient prefers and/or as clothing allows).
Study: NCT05364255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD9833 Oral Solution, 75 mg
Description: Oral Solution, 75 mg (NMT 0.67 MBq) - oral, fasted
Study: NCT06208332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo-Narrative
Description: Photo-Narratives include 1-3 photos of the pediatric patient and their family to tell a story about palliative care topics that are shared with the child's clinicians.
Study: NCT05007444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P2Et (Caesalpinia spinosa extract)
Description: Patients who meet inclusion criteria will begin taking 4000mg daily, distributed in 2 doses with meals of 2000mg of P2Et extract during neoadjuvant treatment. In case of presenting toxicity, it will be lowered to the next dose level, that is, 2000 mg under the same dosage schedule and 1000 mg following the same principle. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard neoadjuvant therapy and will restart 3 days after having passed the cycle. That is, in the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days after the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After determining the optimal biological dose (OBD), the patients will be divided into the placebo arm or the treatment arm. In the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking according to the asignation as stated in the drug intervention.
Study: NCT06420583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTA pulpotomy
Description: 1. Application of rubber dam for isolation, then a standardized access cavity procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove pulpal tissues to the orifice level, bleeding control in the pulp chamber will be achieved by using 5% sodium hypochlorite.~2. gentle condensation of MTA mix in the pulp chamber will be done by a wet sterile cotton pellet and then the rest of the pulp chamber will be filled with Glass Ionomer restoration.~3. The tooth will be restored with a stainless steel crown.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction
Description: After complete Anesthetic application in the affected area, non-surgical extraction will be done.
Study: NCT06322303

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (CBD 0%)
Description: Participants are required to vaporize placebo at 0% CBD concentration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBD 15%
Description: Participants are required to vaporize CBD at a concentration of 15%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBD 30%
Description: Participants are required to vaporize CBD at a concentration of 30%.
Study: NCT04982653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06215716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efruxifermin
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efruxifermin
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT05344703

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Y Balance Plus Visual Perturbations
Description: Stroboscopic glasses will be added to the protocol for the participants to perform the Y-balance lower quarter to examine the differences in Y-balance scores as well as examining the Y-balance's ability to predict injury and concussion with visual perturbations.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Y balance
Description: Subjects will perform Y-balance without any interventional strategies.
Study: NCT04982653

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05791084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application with breathing instructions and a sensor to attach around the chest. To be able to train at home before radiotherapy with DIBH starts.
Description: The DIBH-App consists of 1) a mobile application that patients download to their own smart mobile phone, and 2) associated stretch-sensors that are attached around the chest and connected to the mobile phone via Bluetooth. Visually, the graphics is similar to the software used for DIBH in the RT department. Coaching takes place through instructional videos, text, and audio recordings (Image 2). The following information will be recorded and stored: date and time of practice, outcome of each session (including sensor data and calibration parameters), and user behavior within the application (such as screen visits, FAQ sections viewed, and key button presses).
Study: NCT06095193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: menopause education
Description: Women will be taught the physiology of female reproductive organs, physiology of menopause, vaginal symptoms in menopause, sexual myths in menopause and practices that will support sexuality in menopause, in 50 minutes for 4 weeks.
Study: NCT04982653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo hepatectomy using small bites fascial method for abdominal wall closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo hepatectomy using conventional fascial method for abdominal wall closure
Study: NCT06286943

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short Chain Fatty Acids (SCFAs).
Description: Colon-delivery capsules of SCFAs.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystaline cellulose placebo capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maastricht Acute Stress Task
Description: The Maastricht Acute Stress Task. This 15-minute stress-inducing task consists of a 5-minute preparation phase where instructions about the upcoming tasks are given, followed by a 10-minute acute stress phase where the hand immersion trial (HIT) in ice-cold water and mental arithmetic (MA) task is given interchangeably.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maastricht Acute Stress Task
Description: The Maastricht Acute Stress Task. This 15-minute stress-inducing task consists of a 5-minute preparation phase where instructions about the upcoming tasks are given, followed by a 10-minute acute stress phase where the hand immersion trial (HIT) in ice-cold water and mental arithmetic (MA) task is given interchangeably.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No-stress control task
Description: The placebo version of the MAST follows the same structure of the MAST with none of the stress elements. It uses lukewarm water and simple arithmetic's.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-stress control task
Description: The placebo version of the MAST follows the same structure of the MAST with none of the stress elements. It uses lukewarm water and simple arithmetic's.
Study: NCT05004233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection before antiplatelet treatment
Description: Blood sample (17ml) will be collected in the neurovascular department to be processed for platelet ultrastructural analysis before the onset of an antiplatelet treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection after antiplatelet treatment
Description: A follow-up will be carried out 5 to 8 days after the initiation of the treatment.~A blood test will be taken in the NeuroVascular Unit
Study: NCT06282289

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Magnetoencephalography (MEG)
Description: Stimuli will be presented binaurally through headphones at 60 decibel sound pressure level (dB SPL). Conditions are presented in a pseudo-random order with an inter-stimulus interval of \~800 ms on average (range: 600 ms to 1000 ms). The duration of the stimuli is fixed: 2 seconds, in order to guarantee a minimum number of cycles.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Magnetoencephalography (MEG)
Description: Stimuli will be presented binaurally through headphones at 60 decibel sound pressure level (dB SPL). Conditions are presented in a pseudo-random order with an inter-stimulus interval of \~800 ms on average (range: 600 ms to 1000 ms). The duration of the stimuli is fixed: 2 seconds, in order to guarantee a minimum number of cycles.

Intervention type: OTHER
Group type: OTHER
Intervention: Cognition development questionnaire
Description: Computerised questionnaires completed by parents

Intervention type: OTHER
Group type: OTHER
Intervention: Cognition development questionnaire
Description: Computerised questionnaires completed by parents
Study: NCT05119725

Intervention type: DEVICE
Intervention: continous 3 day EKG monitoring with S-Patch Cardio
Description: continous 3 day EKG monitoring with S-Patch Cardio

Intervention type: DEVICE
Intervention: continous 3 day EKG monitoring with S-Patch Cardio
Description: continous 3 day EKG monitoring with S-Patch Cardio
Study: NCT06102850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention for Young Adults with Mental Health conditions
Description: SIx month supportive intervention involving CTI phased based casemanagement, support from a peer support specialist, and support from a mental health liaison
Study: NCT05108467

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care Lactate
Description: StatStrip Lactate is a handheld, point-of-care (POC) meter that brings lactate testing directly to the bedside. Lactate measured with blood gas analyzers is problematic for bedside care. Blood gas analyzers require arterial samples, large sample volumes (100-200 μL), and long analysis times (up to 2.5 minutes). In addition, blood gas analyzers are complex to use, stationary, and expensive to purchase and run.~StatStrip Lactate testing is as easy as bedside glucose testing. Single-use, pre-calibrated biosensors provide the fastest turnaround time (13 seconds) from the smallest whole blood sample (0.6 μL) with excellent correlation to central laboratory reference methods.

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care Lactate
Description: StatStrip Lactate is a handheld, point-of-care (POC) meter that brings lactate testing directly to the bedside. Lactate measured with blood gas analyzers is problematic for bedside care. Blood gas analyzers require arterial samples, large sample volumes (100-200 μL), and long analysis times (up to 2.5 minutes). In addition, blood gas analyzers are complex to use, stationary, and expensive to purchase and run.~StatStrip Lactate testing is as easy as bedside glucose testing. Single-use, pre-calibrated biosensors provide the fastest turnaround time (13 seconds) from the smallest whole blood sample (0.6 μL) with excellent correlation to central laboratory reference methods.
Study: NCT05351892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Soft gel capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Soft gel capsule, oral
Study: NCT06560372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional realization of a brain perfusion scan sequence which would allow the radiological diagnosis of CV
Description: Neurological monitoring by daily TCD will be carried out.~* If monitoring finds, between 3rd and 12th day of treatment, a neurological deterioration or an uncontrolled increase in intracranial pressure, a new cerebral CT scan will be performed, as recommended in such a case.~* As part of this research, a specific interventional act will be implemented: additional brain perfusion scan sequence which would allow the radiological diagnosis of CV.~* Interventions related to improving cerebral perfusion and reducing intracranial pressure recommended in head trauma patients will be implemented without modification of management linked to protocol.~The additional perfusion sequences will be analyzed independently and blindly by 2 experienced interventional neuroradiologists (double reading blinded to the patient's characteristics).
Study: NCT04260217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG2575 400 mg
Description: APG2575 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG2575 600 mg
Description: APG2575 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG2575 600 mg
Description: APG2575 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG2575 800 mg
Description: APG2575 800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG2575 800 mg
Description: APG2575 800 mg
Study: NCT06142565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nose plug
Description: Participants will complete olfactory training with scented nose plugs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular olfactory training
Description: Participants will complete olfactory training with regular odors found in their home.
Study: NCT05747651

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Total volume of blood (on each sampling occasion): 54,5mL.

Intervention type: BIOLOGICAL
Intervention: Urine sample
Description: Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted.

Intervention type: BIOLOGICAL
Intervention: Saliva sample
Description: Saliva: will be collected in special container for saliva microbiome and methylation.

Intervention type: BIOLOGICAL
Intervention: Stool sample
Description: Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C.

Intervention type: BIOLOGICAL
Intervention: Tissue sample
Description: Tissue samples for organ-specific manifestations:~* Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.
Study: NCT06492850

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FT-002
Description: Intraocular injection of a single dose

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FT-002
Description: Intraocular injection of a single dose
Study: NCT06359522

Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS monitor
Description: NIRS monitoring data will be collected to determine organ perfusion.

Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS monitor
Description: NIRS monitoring data will be collected to determine organ perfusion.
Study: NCT04922528

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Cholecystectomy with Fluorescent Cholangiography
Description: Indocyanine green is a fluorophore molecule which is metabolized by the liver and excreted exclusively through the biliary system. Intra-operatively, near-infared imaging via the laparoscope will be used to visualize the biliary anatomy in the intervention arm, as an adjunct to standard of care white-light imaging.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Cholecystectomy with White Light Imaging
Description: As per the current standard of care, patients undergoing laparoscopic cholecystectomies will have it completed using white light imaging through the laparoscope.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Cholecystectomy with White Light Imaging
Description: As per the current standard of care, patients undergoing laparoscopic cholecystectomies will have it completed using white light imaging through the laparoscope.
Study: NCT05341245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Graphene oxide and open flap debridement
Description: Using Graphene oxide with open flap debridement in management of periodontal intrabony defects in dogs

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open flap debridement
Description: Using Open flap debridement in management of periodontal intrabony defects in dogs
Study: NCT05714332

Intervention type: OTHER
Intervention: Advanced practice physiotherapy and orthopedic surgeon management
Description: Management of their musculoskeletal condition by an advanced practice physiotherapist and an orthopedic surgeon.

Intervention type: OTHER
Intervention: Orthopedic surgeon management
Description: Management of their musculoskeletal condition by an orthopedic surgeon.
Study: NCT04380051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sensory-tonic stimulation
Description: sensory-tonic stimulation done by the parents to the child, five times a week during 15 minutes at each time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin-to-skin contact
Description: skin-to-skin contact left free for parents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: skin-to-skin contact
Description: skin-to-skin contact left free for parents
Study: NCT05728944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine+Brimonidine combination ophthalmic solution
Description: Aceclidine + Brimonidine combination ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine
Description: Aceclidine ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Proprietary vehicle ophthalmic solution
Study: NCT06393400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation with 100 g of healthy donor stool in 36-40 oral capsules once~Other Names:~* FMT~* Stool Transplant~* Poop Transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG3350
Description: Polyethylene Glycol 3350 17 g oral dissolved in 4 litres of water consumed the evening before FMT.~Other Names:~* PEG3350~* RestoraLAX~* MiraLAX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~- Gemzar

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel 125 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~- Abraxane
Study: NCT05206877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, 4 units
Description: Topical insulin 100 U/ml, 1 drop per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, 4 units
Description: Topical insulin 100 U/ml, 1 drop per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, 20 units
Description: Topical insulin 500 U/ml, 1 drop per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, 20 units
Description: Topical insulin 500 U/ml, 1 drop per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin, 4 units twice daily
Description: 1 drop of low dose insulin twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin, 20 units twice daily
Description: 1 drop of high dose insulin twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin, 4 units three times daily
Description: 1 drop of low dose insulin three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin, 20 units three times daily
Description: 1 drop of high dose insulin three times daily.